Search Results

You are looking at 91 - 100 of 257 items for :

  • User-accessible content x
Clear All
Free access

Paige V Bauer and Frank A Duca

. 2015 , Buse et al . 2016 ). Interestingly, this is not the only evidence for a therapeutic role of the gut in diabetes treatment. Over the past decade, incretin-based therapies including glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl

Free access

Jacob Jelsing, Niels Vrang, Søren B van Witteloostuijn, Michael Mark and Thomas Klein

Introduction The incretin hormone glucagon-like peptide 1 (GLP1) is a gut peptide that is secreted in response to nutrient ingestion. It enhances the glucose-dependent stimulation of insulin secretion and also controls blood glucose (BG) via

Free access

Bethany P Cummings, Andrew A Bremer, Timothy J Kieffer, David D'Alessio and Peter J Havel

hypothesized that dexamethasone may enhance postprandial insulin secretion by increasing meal-stimulated incretin hormone secretion and/or by increasing parasympathetic input to the pancreas. The incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose

Free access

Shin Tsunekawa, Naoki Yamamoto, Katsura Tsukamoto, Yuji Itoh, Yukiko Kaneko, Toshihide Kimura, Yoh Ariyoshi, Yoshitaka Miura, Yutaka Oiso and Ichiro Niki

Introduction The beneficial effects of glucagon-like peptide 1 (GLP-1) and its related substances such as inhibitors of dipeptidyl peptidase IV, its degrading enzyme, on the pancreatic β-cells have been reported; these agents enhance

Restricted access

Neil Tanday, Peter R Flatt, Nigel Irwin and R Charlotte Moffett

incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), in T2DM have been linked to direct positive effects at the level of the endocrine pancreas. This includes, but not limited to, potentiation of glucose

Free access

Hidetada Ogata, Yusuke Seino, Norio Harada, Atsushi Iida, Kazuyo Suzuki, Takako Izumoto, Kota Ishikawa, Eita Uenishi, Nobuaki Ozaki, Yoshitaka Hayashi, Takashi Miki, Nobuya Inagaki, Shin Tsunekawa, Yoji Hamada, Susumu Seino and Yutaka Oiso

Introduction Incretins, the gut hormones such as glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP1), which are secreted from enteroendocrine K-cells and L-cells, respectively, following meal ingestion stimulate

Free access

Takaharu Maruyama, Kenichi Tanaka, Jun Suzuki, Hiroyuki Miyoshi, Naomoto Harada, Takao Nakamura, Yasuhisa Miyamoto, Akio Kanatani and Yoshitaka Tamai

). It was also reported that bile acid stimulated glucagon-like peptide-1 (GLP-1) secretion from STC-1 cells via Gpbar1/TGR5 ( Katsuma et al. 2005 ). GLP-1 is secreted from the L-cells in the intestine after meals and indirectly decreases blood glucose

Free access

Dominique A Glauser and Werner Schlegel

, glucagon-like peptide-1 (GLP-1), or glucose-dependent insulinotropic polypeptide (GIP) ( Trumper et al. 2000 , 2001 , Wrede et al. 2002 , Buteau et al. 2006 ). The binding of IGF-I or insulin to their receptors results in the

Free access

Bethany P Cummings, Ahmed Bettaieb, James L Graham, Kimber Stanhope, Fawaz G Haj and Peter J Havel

peroxisome proliferator receptor γ (PPARγ) and glucagon-like peptide 1 (GLP1). PPARγ is a nuclear receptor that is highly expressed in adipose tissue and macrophages and acts to upregulate the expression of factors involved in adipocyte differentiation and

Free access

Yoon Sin Oh, Youn-Jung Lee, Yup Kang, Jaeseok Han, Oh-Kyung Lim and Hee-Sook Jun

-1 (GLP1), a potent gluco-incretin hormone, has an antidiabetic function. It enhances glucose-dependent insulin release, insulin biosynthesis, and β-cell proliferation and suppresses β-cell apoptosis ( Doyle & Egan 2007 ). Exendin-4, a GLP1 receptor